Associate Director, Discovery Process Chemistry

About the role

Revolution Medicines is seeking a motivated individual with a scientific background to play a critical role as a technical leader within the CRO management team in the Medicinal Chemistry function. This position will be responsible for route evaluation and enabling the CRO team to perform reaction condition optimization, and scale-up of key intermediates to support Revolution Medicines Medicinal Chemistry efforts. The qualified candidate will be responsible for enabling the rapid transition of the Medicinal chemistry routes to PDM process chemistry development, the effective communication and collaboration with CRO teams and PDM and leading efficient transitional efforts to enable the PDM team. This role is reporting to the Director of CRO management, Medicinal Chemistry.

Responsibilities

• Work closely with discovery chemistry teams and monitor the progress of the projects and provide support on material needs of building blocks and intermediates and solutions of challenging chemistry.
• Explore the chemistry on route scouting and optimization of key building blocks, intermediates for development candidates, validate the synthetic and analytical protocol, and evaluate the safety of scale up.
• Propose chemistry for building blocks and intermediates, including route evaluation and process optimization utilizing advanced technologies like flow chemistry, photochemistry, biocatalysis etc. to solve complex synthesis challenges.
• Manage internal and external teams to scale up intermediates to support discovery chemistry efforts from gam-scale to kilogram-scale production.
• Improve the overall efficiency of targets synthesis both for discovery chemistry and CMC process chemistry, provide manufacturing friendly solutions on candidate synthesis.
• Manage technology transfer from discovery chemistry to CMC process chemistry and help on process familiarization at CDMOs (contract development and manufacturing organization).
• Work with project team(s) to identify development candidate requirements, manage and optimize aggressive project timelines.
• Write, review, and approve study protocols, manufacturing batch records, and development and campaign reports.
• Communicate effectively within cross functional project teams at Revolution Medicines.
• Stay current with organic chemistry literature and emerging technologies
• Required Skills, Experience and Education:
• Advanced degree (PhD or MS) in organic chemistry or related discipline.
• Minimum of5+ years of relevant experience in Medicinal Chemistry or pharmaceutical process research and development.
• Strong foundation and delivery track record in synthetic organic chemistry.
• Strong Communication skills.
• Proficiency in modern characterization techniques (NMR, LC-MS, HPLC).
• Strong problem-solving skills with sound technically driven decision-making ability.
• Effective written and verbal communication skills and interpersonal skills.
• An innovative team-player with capacity to be effective in a dynamic and fast-paced company environment.
• Preferred Skills:
• PhD in organic chemistry, chemical engineering or related discipline with 5+ years of relevant industry experience in small molecule drug discovery and/or development.
• Previous experience managing projects at CROs/CMOs.
• Knowledge and experience in non-good manufacturing practices (GMP) and GMP API process development, scale-up, and manufacturing is a plus.
• Track record of patents and/or peer-reviewed publications.
• #LI-Hybrid #LI-LN1
• Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity aw

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience